Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 101 publications
CD73 inhibition overcomes adaptive immune resistance to PARP inhibiton in models of prostate cancer.
CD73 inhibition overcomes adaptive immune resistance to PARP inhibiton in models of prostate cancer.
Journal: The Journal of clinical investigation
Published: August 18, 2026
Dual Targeting of Nucleotidase-Dependent and -Independent Functions via PROTAC-Mediated CD73 Degradation.
Journal: Journal of medicinal chemistry
Published: June 29, 2026
IL-15 Complexes Combined with PD-1 Blockade Affect Immune Cell Distribution, Localization, and Immune Signatures in Regressing Versus Non-Regressing Metastatic Breast Tumors.
Journal: International journal of molecular sciences
Published: August 01, 2025
The telomerase vaccine UV1 combined with ipilimumab and nivolumab versus ipilimumab and nivolumab in advanced melanoma (INITIUM): A randomized open-label phase 2 study.
Journal: European journal of cancer (Oxford, England : 1990)
Published: June 27, 2025
Drug-Induced Leukocytoclastic Vasculitis From an Unreported Source: Daptomycin.
Journal: Cureus
Published: April 17, 2025
Indeterminate Cell Histiocytosis and a Review of Current Treatment.
Journal: Cutis
Published: February 13, 2025
4-1BB stimulation with concomitant inactivation of adenosine A2B receptors enhances CD8+ T cell antitumor response.
Journal: The Journal of clinical investigation
Published: January 03, 2025
Efficacy and Safety of Denileukin Diftitox-Cxdl, an Improved Purity Formulation of Denileukin Diftitox, in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 19, 2024
Phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: adrenocortical carcinoma cohort.
Journal: Journal for immunotherapy of cancer
Published: July 09, 2024
Enhancing Therapeutic Efficacy of FLT3 Inhibitors with Combination Therapy for Treatment of Acute Myeloid Leukemia.
Journal: International journal of molecular sciences
Published: June 20, 2024
Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway).
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: May 06, 2024
Last Updated: 09/26/2026